

*AMENDMENTS TO THE CLAIMS*

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Currently Amended) A library of adenoviral vectors, wherein each member of the library comprises (i) a first heterologous DNA encoding ~~a first gene product~~ a vascular endothelial growth factor (VEGF), wherein the first heterologous DNA is common to each member of the library of adenoviral vectors, and (ii) a second heterologous DNA encoding ~~a~~ a second gene product, wherein the second heterologous DNA varies between the members of the library of adenoviral vectors.

2. (Cancelled)

3. (Original) The library of claim 1, wherein the first heterologous DNA and/or the second heterologous DNA is operably linked to an inducible promoter.

4. (Original) The library of claim 1, wherein the first heterologous DNA and the second heterologous DNA are under the control of separate regulatory elements.

5. (Original) The library of claim 1, wherein the first heterologous DNA and the second heterologous DNA are under the control of a bi-directional promoter.

6.-11. (Cancelled)

12. (Original) The library of claim 1, wherein the second gene product is fused to an activation domain, and the first gene product is fused to a DNA binding domain.

13.-53. (Cancelled)

54. (Currently Amended) A library of serotype 35 adenoviral vectors, wherein each member of the library comprises (i) a first heterologous DNA encoding a vascular endothelial growth factor (VEGF) ~~a first gene product~~, wherein the first heterologous DNA is common to each member of the library of adenoviral vectors, and (ii) a second heterologous DNA encoding ~~a~~ a second gene product, wherein the second heterologous DNA varies between the members of the library of adenoviral vectors.